Flamel Technologies, Inc

Latest News

March 8, 2010
Flamel Technologies Announces Fourth Quarter and Year-End 2009 Results

A conference call to discuss the earnings is scheduled for 8:30 AM EST on March 09, 2010.
The dial-in number (for investors in the U.S. and Canada) is 1-877-857-6173; the conference ID number is 2453008.
International investors are invited to dial 1 719-325-4888.
Webcast

March 1, 2010
Flamel Technologies Announces Projected Release Date of Fourth Quarter and Annual Results; Conference Call

December 18, 2009
Flamel Technologies Announces the Initiation of a Phase 2a Clinical Trial of Flamel's IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection

November 16, 2009
Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to $48.8 million
A conference call to discuss earnings is scheduled for 8:30 AM EST November 16, 2009.
The dial-in number (for investors in the U.S. and Canada) is 1-800-860-2442; the conference ID number is 435349.
International investors are invited to dial 1 412-858-4600.
Webcast

November 04, 2009
Flamel Technologies Announces Licensing Agreement with Pfizer

September 18, 2009
Flamel Technologies to Present at UBS Global Life Sciences Conference

Medusa®

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

Micropump® Technologies

From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info

December 18, 2002 Flamel Technologies announces receipt of $1.5 million milestone payment from GlaxoSmithKline for a sachet formulation of controlled release Augmentin®

October 22, 2002 Flamel Technologies announces third quarter earnings of $0.15 per share; increase in cash position to $14.6 million

September 19, 2002 Flamel Technologies announces receipt of $4 million milestone payment from Servier Monde

July 25, 2002 Flamel Technologies announces breakeven quarterly results based on operating achievement; increase in cash position to $11.9 million

July 8, 2002 Flamel Technologies announces license agreement with GlaxoSmithKline for sachet formulation of controlled-release Augmentin®

April 29, 2002 Flamel Technologies announces first quarter results, showing a net profit of $ 0.07 per share

March 12, 2002 Flamel Technologies announces fourth quarter and year-end results: 2001 loss per share narrows to $0.8 per share

January 11, 2002 Flamel Technologies and Servier Monde announce Micropump® license agreement for ACE inhibitor, Flamel paid $3 million upon signing

January 11, 2002 Flamel Technologies announces termination of development agreement with Novo Nordisk for Basulin and reacquisition of rights